This article by Natalie Olivero originally appeared on Military Times, the nation's largest independent newsroom dedicated to covering the military and veteran community.
The Department of Veterans Affairs is launching a nationwide clinical trial to determine whether semaglutide, marketed as Ozempic for Type 2 diabetes and Wegovy for chronic weight management, can help treat alcohol use disorder in veterans, a condition VA says has been diagnosed in more than 400,000 veterans nationwide.
Semaglutide is approved by the Food and Drug Administration to treat Type 2 diabetes and chronic weight management, but not alcohol use disorder.
VA researchers are studying whether the GLP-1 receptor agonist may affect parts of the brain involved in reward, potentially offering a new treatment option for veterans with moderate or severe alcohol use disorder if proven safe and effective.
[TAKE ACTION: Ask Your Lawmakers to Reinstate TRICARE for Life Coverage of GLP-1 Medications]
The department cautioned veterans not to self-medicate or replace evidence-based alcohol use disorder treatments with GLP-1 medications without first consulting a health care provider.
The study, known as the Cessation or Reduction of Alcohol Consumption in Veterans (CRAVE) trial, will enroll more than 600 veterans ages 18 to 80 at 18 VA medical centers nationwide.
Participants with moderate or severe alcohol use disorder will receive weekly injections of either semaglutide or a placebo for 24 weeks, followed by a safety evaluation. Researchers will measure changes in alcohol consumption, overall health and quality of life.
[RELATED: New Medicare GLP-1 Program Excludes TRICARE For Life Beneficiaries]
Researchers at Washington University School of Medicine have increasingly studied whether GLP-1 medications, originally developed for diabetes and later approved for obesity, could also help treat substance use disorders.
VA cited an analysis published in March that found patients taking GLP-1 medications experienced lower rates of alcohol use disorder and other substance use disorders than similar patients taking other diabetes medications.
The department said larger, controlled clinical trials are needed to determine whether semaglutide is safe and effective for treating alcohol use disorder.
In an official statement, VA Secretary Doug Collins said, “By exploring emerging treatment options like the use of a GLP-1 for AUD, we aim to expand the tools available to help Veterans take control of their health and recovery.”
Recruitment began July 28. Veterans interested in participating can contact their local VA medical center or search for the trial on ClinicalTrials.gov.
Other articles by Military Times:
Army sunsets legendary Buffalo Soldiers unit
South Carolina military base to be renamed after Lindsey Graham
US military may require some troops in Mideast to surrender cell phones, sources say
Get Help Navigating VA Benefits
Questions about VA benefits? Start here. PREMIUM and LIFE Members have direct access to our webinar archive with to-the-point information on everything from claims and appeals to concurrent receipt to home loans and more.